Literature DB >> 15749673

Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.

Claudine Lapouméroulie, Malika Benkerrou, Marie Hélène Odièvre, Rolande Ducrocq, Manuel Brun, Jacques Elion.   

Abstract

Plasma endothelin-1 (ET-1) is elevated in patients with sickle cell disease (SCD). Hydroxyurea (HU) is the only drug with demonstrated clinical efficacy in SCD. Here we show that treatment with HU results in a decreased concentration of circulating ET-1 which is not correlated with the HU-induced increase in HbF level. Blunting of the ET-1 vasoconstrictive stimulus could contribute to the beneficial effects of HU.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15749673

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  14 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.

Authors:  Vicky Chaar; Sandrine Laurance; Claudine Lapoumeroulie; Sylvie Cochet; Maria De Grandis; Yves Colin; Jacques Elion; Caroline Le Van Kim; Wassim El Nemer
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

3.  Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia.

Authors:  Rhiannon R Penkert; Julia L Hurwitz; Paul Thomas; Jason Rosch; Jola Dowdy; Yilun Sun; Li Tang; Jane S Hankins
Journal:  Haematologica       Date:  2017-11-16       Impact factor: 9.941

4.  Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.

Authors:  Sandrine Laurance; Pauline Lansiaux; François-Xavier Pellay; Michelle Hauchecorne; Arndt Benecke; Jacques Elion; Claudine Lapoumeroulie
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

5.  Sensitization to acute procedural pain in pediatric sickle cell disease: modulation by painful vaso-occlusive episodes, age, and endothelin-1.

Authors:  Alyssa M Schlenz; Catherine B McClellan; Teresa R M Mark; Alvin D McKelvy; Eve Puffer; Carla W Roberts; Sarah M Sweitzer; Jeffrey C Schatz
Journal:  J Pain       Date:  2012-05-24       Impact factor: 5.820

6.  Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.

Authors:  Terika P Smith; Alyssa M Schlenz; Jeffrey C Schatz; Rangan Maitra; Sarah M Sweitzer
Journal:  Blood Cells Mol Dis       Date:  2014-11-26       Impact factor: 3.039

7.  Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.

Authors:  Matthew Olnes; Amy Chi; Carissa Haney; Rose May; Caterina Minniti; James Taylor; Gregory J Kato
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

8.  Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factor.

Authors:  Xunde Wang; Laurel Mendelsohn; Heather Rogers; Susan Leitman; Nalini Raghavachari; Yanqin Yang; Yu Ying Yau; Michael Tallack; Andrew Perkins; James G Taylor; Constance Tom Noguchi; Gregory J Kato
Journal:  Blood       Date:  2014-06-10       Impact factor: 22.113

9.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

Review 10.  Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature.

Authors:  Uzoma A Anele; A Kyle Mack; Linda M S Resar; Arthur L Burnett
Journal:  Int Urol Nephrol       Date:  2014-05-14       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.